Today: 10 June 2026
GE Vernova stock price jumps 4% ahead of earnings as traders hunt for guidance
27 January 2026
2 mins read

GE Vernova stock price jumps 4% ahead of earnings as traders hunt for guidance

New York, January 27, 2026, 13:07 (EST) — Regular session

Shares of GE Vernova Inc. (NYSE: GEV) jumped about 4.1% to $693.27 by midday Tuesday, beating a jittery U.S. market ahead of earnings. The stock hit an intraday high of $694.63 after opening at $676.17, with volume around 2.2 million shares.

The news comes just a day before GE Vernova is set to report its Q4 and full-year 2025 results. The company will publish the numbers ahead of U.S. market open on Wednesday. CEO Scott Strazik and CFO Ken Parks are scheduled to break down the details in a webcast at 7:30 a.m. ET.

Why it matters now: GE Vernova’s shares have been creeping closer to recent highs amid rising anticipation for its earnings report. The stock closed Monday at $665.99, about $65 below its 52-week peak of $731 reached on Dec. 10, per MarketWatch data.

The broader market sent mixed signals. The S&P 500 crept up 0.22%, while the Nasdaq 100 rose 0.44% by midday. The Dow, in contrast, dropped 0.64%, data from Nasdaq.com showed.

Analysts at Zacks Equity Research forecast earnings per share hitting $3.03, up roughly 75% from last year, on revenues of $10.04 billion. Yet, sales are expected to fall about 5%. The firm pointed to softer outlooks in the wind segment, with revenue set to drop nearly 29% year over year. At the same time, electrification revenue is forecast to rise around 23%.

The bull case still leans on rising power demand from data centers, pushing up orders for grid gear and gas turbines. In December, GE Vernova forecasted revenue between $41 billion and $42 billion for 2026, with free cash flow expected to range from $4.5 billion to $5.0 billion. The company also expanded its share buyback program to $10 billion and doubled its quarterly dividend to 50 cents.

At its December investor day, William Blair analyst Jed Dorsheimer called the event “firing on all cylinders,” pointing to turbine production slots secured through 2028. GE Vernova said it expects to reach 80 gigawatts of signed combined-cycle gas turbine contracts by year-end and aims to boost gas-turbine output to about 20 GW by mid-2026. Competitors Siemens Energy and Mitsubishi Heavy Industries have also raised their targets. Reuters

Traders are zeroed in not just on whether GE Vernova beats earnings but on the stock’s reaction around earnings events. Benzinga data showed GE Vernova missed EPS estimates by $0.19 last quarter, yet its shares rose 3.32% the next day. This underscores how guidance often trumps the reported numbers.

Risks can surface quickly, especially when it comes to specialist material supply. In December, Strazik revealed the company’s collaboration with the U.S. government to boost yttrium stockpiles — a rare earth element vital for energy, aerospace, and semiconductors — following China’s tighter export controls. “We are very focused on it every day,” he said. Prices outside China soared about 4,400% from January to November 2025, highlighting how fast costs can jump. Reuters

Investors are bracing for the Jan. 28 update, keen to spot any shifts in 2026 outlooks, especially in power and electrification. They’ll also watch closely for clues that the wind segment’s troubles might be stabilizing. The guidance—and the mood on the earnings call—could steer the stock’s next move once trading resumes.

Stock Market Today

  • Apotex Debuts on Toronto Stock Exchange in Largest Life Sciences IPO
    June 10, 2026, 10:06 AM EDT. The Toronto Stock Exchange (TSX) welcomed Apotex Health Corp., marking the largest life sciences initial public offering (IPO) by total proceeds on the exchange, raising $1.3 billion. Apotex, a Canadian global health company, began trading under the symbol APTX on June 11, 2026. The listing reflects the strength of Canadian capital markets and underscores growth in the life sciences sector, which counts 110 companies listed on TSX and TSX Venture Exchange with a combined market capitalization of $26 billion. Apotex provides a wide range of affordable medicines including generics and biosimilars, serving millions worldwide from its Toronto headquarters and global offices. TSX CEO Loui Anastasopoulos praised the listing as showcasing Canadian competitiveness on the global stage.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Previous Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Apple stock climbs as Wall Street targets shift ahead of Jan. 29 earnings
Next Story

Apple stock climbs as Wall Street targets shift ahead of Jan. 29 earnings

Go toTop